Children born small for gestational age

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL Acta Facultatis Medicae Naissensis Pub Date : 2023-01-01 DOI:10.5937/afmnai40-39513
Jelena Miolski, Maja Ješić, Vlada Bojić, S. Kovačević, J. Blagojević, V. Zdravković
{"title":"Children born small for gestational age","authors":"Jelena Miolski, Maja Ješić, Vlada Bojić, S. Kovačević, J. Blagojević, V. Zdravković","doi":"10.5937/afmnai40-39513","DOIUrl":null,"url":null,"abstract":"Introduction/Aim. Those born small for gestational age are all newborns whose weight, length and head circumference deviate by more than minus two standard deviations in relation to the same parameters of average children of the same sex, corresponding gestational age and population. The goal is their early recognition and adequate treatment. They should be clearly distinguished from premature babies, children born before the 37th week of gestation, and it should be noted that all children born small for gestational age are always born after intrauterine growth arrest. Poor and economically underdeveloped countries show a higher prevalence of children small for gestational age. At birth, these children have a higher risk of asphyxia, infections, neurological disorders, and in the later period of life, low growth, cognitive dysfunctions, disorders of pubertal development and metabolic syndrome. If they have not achieved growth compensation by the age of four and their height is less than minus 2.5 standard deviations, treatment with recombinant growth hormone is suggested. The recommended starting dose of growth hormone is 35 mg/kg of body weight per day. Adequate adjustment of the dose is achieved by monitoring the growth rate at 6 - 12 and IGF-1 at 3 - 6 months after starting therapy, and then once a year. The treatment is stopped in the period of adolescence, when the growth rate is < 2 cm per year. Conclusion. Early recognition of children born small for gestational age provides the opportunity to avoid numerous complications later in life with adequate and timely treatment.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":"86 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai40-39513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Introduction/Aim. Those born small for gestational age are all newborns whose weight, length and head circumference deviate by more than minus two standard deviations in relation to the same parameters of average children of the same sex, corresponding gestational age and population. The goal is their early recognition and adequate treatment. They should be clearly distinguished from premature babies, children born before the 37th week of gestation, and it should be noted that all children born small for gestational age are always born after intrauterine growth arrest. Poor and economically underdeveloped countries show a higher prevalence of children small for gestational age. At birth, these children have a higher risk of asphyxia, infections, neurological disorders, and in the later period of life, low growth, cognitive dysfunctions, disorders of pubertal development and metabolic syndrome. If they have not achieved growth compensation by the age of four and their height is less than minus 2.5 standard deviations, treatment with recombinant growth hormone is suggested. The recommended starting dose of growth hormone is 35 mg/kg of body weight per day. Adequate adjustment of the dose is achieved by monitoring the growth rate at 6 - 12 and IGF-1 at 3 - 6 months after starting therapy, and then once a year. The treatment is stopped in the period of adolescence, when the growth rate is < 2 cm per year. Conclusion. Early recognition of children born small for gestational age provides the opportunity to avoid numerous complications later in life with adequate and timely treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
出生时小于胎龄的婴儿
介绍/目标。小于胎龄出生者,是指体重、体长和头围与同性别、相应胎龄和人口平均儿童的相同参数偏差大于- 2个标准差的新生儿。我们的目标是尽早发现并给予适当的治疗。应与早产儿、妊娠37周前出生的儿童明确区分,并应注意所有出生时小于胎龄的儿童都是在宫内生长停止后出生的。在贫穷和经济不发达的国家,小于胎龄儿童的发生率更高。在出生时,这些儿童有较高的窒息、感染、神经障碍的风险,在生命后期,有生长迟缓、认知功能障碍、青春期发育障碍和代谢综合征的风险。如果他们在四岁之前没有达到生长补偿,并且他们的身高小于- 2.5个标准差,建议使用重组生长激素治疗。生长激素的推荐起始剂量为每天每公斤体重35毫克。在开始治疗后6 - 12个月监测生长速率,在3 - 6个月监测IGF-1生长速率,然后每年监测一次,从而充分调整剂量。当生长速度每年< 2厘米时,在青春期停止治疗。结论。早期识别出生时小于胎龄的儿童可提供机会,通过适当和及时的治疗避免生命后期的许多并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Facultatis Medicae Naissensis
Acta Facultatis Medicae Naissensis MEDICINE, GENERAL & INTERNAL-
CiteScore
0.70
自引率
0.00%
发文量
13
审稿时长
12 weeks
期刊最新文献
Aesthetic appearance assessment in adolescents with idiopathic scoliosis A case of bizarre parosteal osteochondromatous proliferation (Nora's lesion): A brief description N-[2-(5-methoxy-1h-indole-3-yl)ethyl]acetamide may correct arterial hypertension in people with sleep problems Can continuous glucose monitoring be used as a new tool for diagnosing white coat hyperglycaemia and possibly some other entities? Overview of the possibility of bone replacement for the purpose of pre-prosthetic preparation of the patient
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1